Developments Lexaria reaches full enrollment in study evaluating oral DHT-sema against Wegovy Lexaria Bioscience (NASDAQ: LEXX) has announced that full enrollment has been reached and dosing continues on schedule with Human Pilot Study #7 (GLP-1-H26-7) evaluating two oral DehydraTECH-semaglutide (DHT-sema)... October 21, 2026